Revision to company-proposed multiple sclerosis indication urged by FDA Peripheral & Central Nervous System Drugs Advisory Committee in unanimous vote for approval Jan. 28. Committee members suggested FDA emphasize that the drug is for slowing the accumulated neurological disability and reducing relapse rate in clinically worsening secondary progressive or relapsing remitting MS. Immunex is seeking an indication for Novantrone "to slow the progression of neurologic disability and reduce the relapse rate in patients with progressive multiple sclerosis." Novantrone is already approved for the treatment of acute non-lymphocytic leukemia and for patients with symptomatic hormone-refractory prostate cancer
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth